Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) (SCIGG-124)

Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD55 and anti-HLA-A IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.

Datasheet

Specifications

Targets

CD55 & HLA-A

Type

Single chain IgGs

Species Reactivity

Human

Target 1

CD55

Host Animal 1

Mouse

Target 2

HLA-A

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC); Solid tumors

Targets

Target 1

CD55

Gene ID

1604

UniProt ID

P08174

Alternative Names

CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CR; TC; DAF; CROM; complement decay-accelerating factor; CD55 antigen

Target 2

HLA-A

Gene ID

3105

UniProt ID

P30443

Alternative Names

HLA-A; major histocompatibility complex, class I, A; HLAA; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Email: